Digestive diseases and sciences · 2026
Prevalence and Costs of Non-esophageal Eosinophilic Gastrointestinal Diseases in the United States.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aleman Stefani, Anderson Chelsea, Jensen Elizabeth T, Dellon Evan S
Аннотация
BACKGROUND: While the prevalence of eosinophilic esophagitis (EoE) has increased, estimates of prevalence trends for non-esophageal eosinophilic gastrointestinal disease (EGIDs) are limited and costs associated with these conditions are unknown.
AIMS: To estimate prevalence and healthcare costs for non-esophageal EGIDs in the U.S.
METHODS: We analyzed two national health insurance claims databases, MarketScan (2009-2022) and Medicare (2009-2017), to calculate annual prevalence and healthcare cost for patients with ≥ 1 ICD-9/10 code for eosinophilic gastritis or gastroenteritis (EoG/EGE) or eosinophilic colitis (EoC). Estimates were age and sex-standardized to the 2020 U.S. Census data. Inflation adjusted costs included inpatient, outpatient, and pharmaceutical claims for the latest study year.
RESULTS: Prevalence rates were 5.49/100,000 and 11.47/100,000 for EoG/EGE, and 1.95/100,000 and 7.91/100,000 for EoC, in MarketScan and Medicare, respectively. While overall prevalence increased modestly, EoC prevalence increased 2.7-fold in Medicare. Standardized to the U.S. population, prevalence was 6.6/100,000 for EoG/EGE and 3.0/100,000 for EoC, equal to 21,733 EoG/EGE and 9,944 EoC cases. The total healthcare costs were $2.08 million in 2022 for MarketScan and $3.87 million in 2017 for Medicare, mostly attributed to outpatient procedures. Extrapolated national one-year costs adjusted for 2022 inflation totaled $114 million.
CONCLUSIONS: For all non-esophageal EGIDs combined, there was a modest increase in prevalence over the last decade, yet non-esophageal EGIDs remained rare. Notably, EoC demonstrated a nearly three-fold increase among Medicare beneficiaries. Consistent with this finding, costs and burden of disease are highest among Medicare enrollees, suggesting older patients have more complex non-esophageal EGID healthcare needs.
AIMS: To estimate prevalence and healthcare costs for non-esophageal EGIDs in the U.S.
METHODS: We analyzed two national health insurance claims databases, MarketScan (2009-2022) and Medicare (2009-2017), to calculate annual prevalence and healthcare cost for patients with ≥ 1 ICD-9/10 code for eosinophilic gastritis or gastroenteritis (EoG/EGE) or eosinophilic colitis (EoC). Estimates were age and sex-standardized to the 2020 U.S. Census data. Inflation adjusted costs included inpatient, outpatient, and pharmaceutical claims for the latest study year.
RESULTS: Prevalence rates were 5.49/100,000 and 11.47/100,000 for EoG/EGE, and 1.95/100,000 and 7.91/100,000 for EoC, in MarketScan and Medicare, respectively. While overall prevalence increased modestly, EoC prevalence increased 2.7-fold in Medicare. Standardized to the U.S. population, prevalence was 6.6/100,000 for EoG/EGE and 3.0/100,000 for EoC, equal to 21,733 EoG/EGE and 9,944 EoC cases. The total healthcare costs were $2.08 million in 2022 for MarketScan and $3.87 million in 2017 for Medicare, mostly attributed to outpatient procedures. Extrapolated national one-year costs adjusted for 2022 inflation totaled $114 million.
CONCLUSIONS: For all non-esophageal EGIDs combined, there was a modest increase in prevalence over the last decade, yet non-esophageal EGIDs remained rare. Notably, EoC demonstrated a nearly three-fold increase among Medicare beneficiaries. Consistent with this finding, costs and burden of disease are highest among Medicare enrollees, suggesting older patients have more complex non-esophageal EGID healthcare needs.